A pair of Rutgers professors have partnered with a former colleague to form a startup with the goal of developing novel cancer treatments based on the use of antibody drug conjugates.
Rutgers researchers found that over 90% of nearly 250,000 comments on proposed rules were form letters, and nearly half the letters contained industry content.